PVR and acute myeloid leukemia: Our results highlight the importance of the TIGIT-PVR/PVRL2 axis for the prognosis of AML patients under standard chemotherapy, implying that immune effects are also operational in this setting, since a high PVR and PVRL2 expression correlated with shorter overall survival in two independent patient cohorts.